Fidaxomicin for the treatment of

Anti-Bacterial Agents / chemistry Clinical Trials as Topic Clostridioides difficile / drug effects Clostridium Infections / drug therapy Fidaxomicin / chemistry Humans Treatment Outcome United States
C. difficile Clostridioides difficile Gram-positive bacteria antibiotics fidaxomicin gastrointestinal infections infection infectious disease therapeutics pediatrics pharmacokinetics/pharmacodynamics

Journal

Future microbiology
ISSN: 1746-0921
Titre abrégé: Future Microbiol
Pays: England
ID NLM: 101278120

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 28 7 2020
medline: 14 10 2021
entrez: 28 7 2020
Statut: ppublish

Résumé

Fidaxomicin is an oral narrow-spectrum novel 18-membered macrocyclic antibiotic that was initially approved in 2011 by the US FDA for the treatment of

Identifiants

DOI: 10.2217/fmb-2020-0104 PMID: 32715754 PMC: PMC8097504
pubmed: 32715754
doi: 10.2217/fmb-2020-0104
pmc: PMC8097504
doi:

Substances chimiques

Anti-Bacterial Agents 0
Fidaxomicin Z5N076G8YQ

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

967-979

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI123525
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI149000
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI144549
Pays : United States

Références

N Engl J Med. 2002 Jan 31;346(5):334-9
pubmed: 11821511
J Bacteriol. 2008 Apr;190(7):2505-12
pubmed: 18245298
Clin Infect Dis. 2012 Aug;55 Suppl 2:S132-42
pubmed: 22752862
J Antibiot (Tokyo). 1975 Apr;28(4):253-9
pubmed: 807545
Lancet Infect Dis. 2012 Apr;12(4):281-9
pubmed: 22321770
J Pediatr Gastroenterol Nutr. 2010 Jul;51(1):2-7
pubmed: 20512057
J Antibiot (Tokyo). 1975 Apr;28(4):247-52
pubmed: 1150527
J Infect. 2010 Jul;61(1):1-8
pubmed: 20361997
Clin Infect Dis. 2012 Aug;55 Suppl 2:S116-20
pubmed: 22752859
Clin Infect Dis. 2012 Aug;55 Suppl 2:S127-31
pubmed: 22752861
J Bacteriol. 2010 Oct;192(19):4983-90
pubmed: 20675492
J Infect Chemother. 2018 Sep;24(9):744-752
pubmed: 29934056
Antimicrob Agents Chemother. 2008 Apr;52(4):1391-5
pubmed: 18268081
Pediatr Infect Dis J. 2015 Mar;34(3):261-6
pubmed: 25247582
Clin Microbiol Infect. 2015 Feb;21(2):164-70
pubmed: 25658560
Toxins (Basel). 2016 May 03;8(5):
pubmed: 27153087
Am J Clin Oncol. 1987 Oct;10(5):451-2
pubmed: 3477943
Drugs. 2013 Oct;73(15):1733-47
pubmed: 24136090
J Antimicrob Chemother. 2019 Jan 1;74(1):6-10
pubmed: 30247587
Antimicrob Agents Chemother. 2012 May;56(5):2493-503
pubmed: 22290948
Clin Infect Dis. 2000 Oct;31(4):995-1000
pubmed: 11049782
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9
pubmed: 21709084
Antimicrob Agents Chemother. 2004 Nov;48(11):4430-4
pubmed: 15504874
J Virol. 1980 Mar;33(3):945-53
pubmed: 6767859
Dig Liver Dis. 2015 Oct;47(10):842-6
pubmed: 26141927
Int J Antimicrob Agents. 2012 Jul;40(1):1-8
pubmed: 22398198
Ann N Y Acad Sci. 2013 Jul;1291:33-41
pubmed: 23672600
J Pediatr. 2009 Jun;154(6):854-8
pubmed: 19230908
J Antibiot (Tokyo). 1987 May;40(5):567-74
pubmed: 3610815
Clin Infect Dis. 2014 Aug 1;59(3):401-3
pubmed: 24785235
J Clin Microbiol. 2017 May;55(5):1244-1248
pubmed: 28275072
Antimicrob Agents Chemother. 2015 Nov 02;60(1):418-23
pubmed: 26525793
Antimicrob Agents Chemother. 2004 Dec;48(12):4898-902
pubmed: 15561877
Antimicrob Agents Chemother. 2014 May;58(5):2934-7
pubmed: 24550338
N Engl J Med. 2011 Feb 3;364(5):422-31
pubmed: 21288078
J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):210-218
pubmed: 28575523
Clin Microbiol Rev. 2013 Jul;26(3):604-30
pubmed: 23824374
Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):305-12
pubmed: 26744587
Trends Microbiol. 2012 Jul;20(7):313-9
pubmed: 22595318
Inflamm Bowel Dis. 2013 Dec;19(13):2744-52
pubmed: 24145927
Clin Infect Dis. 2014 Aug 1;59(3):345-54
pubmed: 24799326
Arch Intern Med. 1986 Jan;146(1):95-100
pubmed: 3942469
Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43
pubmed: 22610025
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
Lancet Infect Dis. 2018 Mar;18(3):296-307
pubmed: 29273269
Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S32-4
pubmed: 20929364
Infect Control Hosp Epidemiol. 2011 Apr;32(4):387-90
pubmed: 21460491
Expert Rev Anti Infect Ther. 2011 Jul;9(7):767-77
pubmed: 21810048
JAMA Intern Med. 2013 Jul 22;173(14):1359-67
pubmed: 23780507
Clin Microbiol Infect. 2012 Dec;18 Suppl 6:5-12
pubmed: 23121549
Emerg Infect Dis. 2010 Apr;16(4):604-9
pubmed: 20350373
Clin Infect Dis. 2007 Aug 1;45(3):302-7
pubmed: 17599306
Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9
pubmed: 21844318
Therap Adv Gastroenterol. 2012 Nov;5(6):395-402
pubmed: 23152733
Pediatr Infect Dis J. 2012 Feb;31(2):134-8
pubmed: 22031485
Medicine (Baltimore). 2017 Mar;96(10):e6231
pubmed: 28272217
Clin Infect Dis. 2013 Oct;57(8):1094-102
pubmed: 23881150
J Antimicrob Chemother. 2013 Mar;68(3):515-22
pubmed: 23208832
Infect Control Hosp Epidemiol. 2014 Sep;35 Suppl 2:S48-65
pubmed: 25376069
Clin Infect Dis. 1993 Jul;17(1):109-13
pubmed: 8353229
Pediatr Infect Dis J. 2019 Jan;38(1):32-36
pubmed: 29601446
Clin Infect Dis. 2008 Jul 1;47(1):63-5
pubmed: 18491959
Antimicrob Agents Chemother. 2006 Jan;50(1):401-2
pubmed: 16377724
Curr Opin Infect Dis. 2013 Aug;26(4):338-44
pubmed: 23743816
Antimicrob Agents Chemother. 2008 Nov;52(11):4163-5
pubmed: 18725442
Clin Infect Dis. 2012 Aug;55 Suppl 2:S162-9
pubmed: 22752866
Clin Infect Dis. 2020 Dec 17;71(10):2589-2591
pubmed: 31773137
J Pediatric Infect Dis Soc. 2012 Sep;1(3):230-43
pubmed: 23687578
Arch Pediatr Adolesc Med. 2011 May;165(5):451-7
pubmed: 21199971
Clin Infect Dis. 2020 May 6;70(10):2095-2102
pubmed: 31253983
Clin Infect Dis. 2012 Feb 15;54(4):568-74
pubmed: 22156854
J Hosp Infect. 2011 Jan;77(1):11-5
pubmed: 21129821
J Antimicrob Chemother. 2014 Jan;69(1):41-4
pubmed: 23887866
Ther Clin Risk Manag. 2008 Dec;4(6):1343-58
pubmed: 19337440
Clin Infect Dis. 2020 Dec 17;71(10):2581-2588
pubmed: 31773143
J Infect Dis. 2015 Nov 15;212(10):1656-65
pubmed: 25920320
N Engl J Med. 1994 Jan 27;330(4):257-62
pubmed: 8043060
J Pediatr Gastroenterol Nutr. 2000 Sep;31(3):220-31
pubmed: 10997362
Pediatr Infect Dis J. 2017 Apr;36(4):379-383
pubmed: 27977555
J Infect Dis. 2008 Feb 1;197(3):435-8
pubmed: 18199029
Antimicrob Agents Chemother. 2013 Jan;57(1):664-7
pubmed: 23147724
Infect Control Hosp Epidemiol. 2009 Oct;30(10):945-51
pubmed: 19732008
Pediatrics. 2008 Dec;122(6):1266-70
pubmed: 19047244
Clin Infect Dis. 2011 Sep;53(5):440-7
pubmed: 21844027
Nat Rev Dis Primers. 2016 Apr 07;2:16020
pubmed: 27158839
Infect Drug Resist. 2014 Mar 17;7:63-72
pubmed: 24669194
PLoS One. 2016 Aug 24;11(8):e0161200
pubmed: 27556739
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31085514
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
N Engl J Med. 2020 Apr 2;382(14):1320-1330
pubmed: 32242357
Open Forum Infect Dis. 2019 Nov 14;6(12):ofz492
pubmed: 31950069
Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2
pubmed: 15155234
Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9
pubmed: 17517836
Clin Infect Dis. 2012 Aug;55 Suppl 2:S143-8
pubmed: 22752863
Gastroenterology Res. 2011 Jun;4(3):93-96
pubmed: 27942322

Auteurs

Andrew M Skinner (AM)

Department of Medicine, Division of Infectious Diseases, Loyola University Medical Center, Maywood, IL, USA.
ORCID: 0000-0001-9452-9316

Tonya Scardina (T)

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.

Larry K Kociolek (LK)

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Department of Pediatrics, Division of Pediatric Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
ORCID: 0000-0002-8756-3417

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Fidaxomicin for the treatment of
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Fidaxomicin for the treatment of
questionsmedicales.fr › Bactéries › Firmicutes › Clostridiales › Clostridioides › Clostridium difficile › Fidaxomicin for the treatment of
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Clostridium › Fidaxomicin for the treatment of
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Polycétides › Macrolides › Fidaxomicine › Fidaxomicin for the treatment of
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Fidaxomicin for the treatment of
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Fidaxomicin for the treatment of
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › États-Unis › Fidaxomicin for the treatment of